Coral Laboratories Limited Stock

Equities

CORALAB6

INE683E01017

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:53 2024-04-19 am EDT 5-day change 1st Jan Change
371.4 INR -0.15% Intraday chart for Coral Laboratories Limited -4.29% -14.65%
Sales 2022 756M 9.07M Sales 2023 781M 9.37M Capitalization 818M 9.81M
Net income 2022 90M 1.08M Net income 2023 64M 768K EV / Sales 2022 0.97 x
Net cash position 2022 182M 2.19M Net cash position 2023 300M 3.6M EV / Sales 2023 0.66 x
P/E ratio 2022
10.1 x
P/E ratio 2023
12.7 x
Employees 109
Yield 2022 *
-
Yield 2023
-
Free-Float 21.78%
More Fundamentals * Assessed data
Dynamic Chart
Coral Laboratories Limited Announces Change in Registered Office Address CI
Coral Laboratories Limited Announces Resignation of Shifa Memon as Company Secretary, Compliance Officer and Key Managerial Personnel CI
Coral Laboratories Limited Appoints Shifa Memon as Company Secretary and Compliance Officer, with Effect from March 9, 2024 CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Coral Laboratories Limited Announces Change in Registered Office Address CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Coral Laboratories Limited Approves the Shifting of Registered Office CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Coral Laboratories Limited Approves Alteration of Memorandum of Association CI
Coral Laboratories Limited Proposes Alteration of Memorandum of Association of the Company CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
More news
1 day-0.15%
1 week-4.29%
1 month-3.34%
3 months-17.34%
6 months+26.35%
Current year-14.65%
More quotes
1 week
365.00
Extreme 365
386.10
1 month
365.00
Extreme 365
410.00
Current year
344.90
Extreme 344.9
470.00
1 year
225.00
Extreme 225
498.10
3 years
217.00
Extreme 217
582.30
5 years
81.20
Extreme 81.2
582.30
10 years
81.20
Extreme 81.2
1 190.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 47 17-05-25
Members of the board TitleAgeSince
Director/Board Member 51 14-08-11
Director/Board Member 43 17-05-25
Director of Finance/CFO 47 17-05-25
More insiders
Date Price Change Volume
24-04-19 371.4 -0.15% 814
24-04-18 372 +1.07% 535
24-04-16 368 -2.01% 1,852
24-04-15 375.6 -3.22% 655
24-04-12 388 +1.53% 1,364

Delayed Quote Bombay S.E., April 19, 2024 at 06:00 am EDT

More quotes
Coral Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical formulations. The Company is engaged in the manufacturing of generic - branded, nutraceuticals, over the counter (OTC) and herbal medicines. It offers dosage forms, which include tablets, capsules, liquid orals, injections (liquids and powder), ointment and creams, gels and lotions, and suppositories. Its product categories include nutraceutical, OTC, sterile and non-sterile. Its nutraceutical products include DAX 200, DAX 400 Drops, Zest drops and Super Zestcal Tablets. Its OTC products include herbal range, skin care, medical devices and effervescent range. Its sterile products include small volume liquid - injectables, lyophilized range - injectables, eye drops and ear drops. Its non-sterile antibiotics/antibacterials, antifungals, gastro-intestinal drugs, anti-emetics and muscle relaxants. The Company also exports its products to various countries.
More about the company
  1. Stock Market
  2. Equities
  3. CORALAB6 Stock